BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kan H, Imamura M, Uchida T, Hiraga N, Hayes CN, Tsuge M, Abe H, Aikata H, Makokha GN, Chowdhury S, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing. J Infect Dis 2016;214:1687-94. [DOI: 10.1093/infdis/jiw437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Sun J, Yogarajah T, Lee RCH, Kaur P, Inoue M, Tan YW, Chu JJH. Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. Sci Rep 2020;10:8159. [PMID: 32424333 DOI: 10.1038/s41598-020-65152-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, Saito Y, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure. J Gen Virol 2018;99:1058-65. [PMID: 29916799 DOI: 10.1099/jgv.0.001091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Hamana A, Takahashi Y, Uchida T, Nishikawa M, Imamura M, Chayama K, Takakura Y. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus. Antiviral Res 2017;146:130-8. [PMID: 28864074 DOI: 10.1016/j.antiviral.2017.08.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Teraoka Y, Uchida T, Imamura M, Osawa M, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K; Hiroshima Liver Study Group. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochem Biophys Res Commun. 2018;500:152-157. [PMID: 29621544 DOI: 10.1016/j.bbrc.2018.04.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
5 Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. J Med Virol 2020;92:210-8. [PMID: 31584207 DOI: 10.1002/jmv.25602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Tang S, Peng ZG, Li YH, Zhang X, Fan TY, Jiang JD, Wang YX, Song DQ. Synthesis and biological evaluation of tricyclic matrinic derivatives as a class of novel anti-HCV agents. Chem Cent J 2017;11:94. [PMID: 29086870 DOI: 10.1186/s13065-017-0327-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Lee SH, Moon JS, Pak BY, Kim GW, Lee W, Cho H, Kim S, Kim SJ, Oh JW. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep 2018;8:12469. [PMID: 30127498 DOI: 10.1038/s41598-018-30460-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]